Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Obrixtamig in SCLC and Other Neuroendocrine Neoplasms Expressing DLL3
NCT04429087Phase 1Active, not recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2020
- Primary completion
- Aug 2026
- Modality
- Prophylactic Vaccines, Antibody Conjugates, Bispecific Antibodies
- Countries
- 4
01
Overview
Phase 1, open-label trial of obrixtamig in Small Cell Lung Cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC) and neuroendocrine carcinoma (NEC) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Maximum Tolerated Dose up to 36 months and Dose-Limiting Toxicities up to 36 months. Started Jul 2020; status: active, not recruiting.
02
Drugs
obrixtamig
03
Conditions
Small Cell Lung Cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)neuroendocrine carcinoma (NEC)
Beyond the preview
Go deeper on NCT04429087.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04429087.